An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec/Gleevec - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase [EXTENSION OF 700013077]
Latest Information Update: 17 Dec 2015
Price :
$35 *
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- 15 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Feb 2013 New trial record